Get started
Work

563eP The good, the bad, and the manageable: Real-world outcomes with CDK4/6 inhibitors

Year: 2026
Type: article
Abstract: CDK4/6 inhibitors combined with endocrine therapy are the standard first-line treatment for HR+/HER2− metastatic breast cancer. While similarly effective, palbociclib, ribociclib, and abemaciclib show distinct safety profiles. This study evaluated the relationship between treatment-related toxicity and clinical outcomes.
Source: ESMO Open
DOI: 10.1016/j.esmoop.2026.107583
Authors: A. Paulet, S. Mancini, K. Shtembari, R. Petrioli, D. Generali, G. Roviello, M. Catalano, C. De Angelis
Institutions: Azienda Ospedaliero-Universitaria Careggi, University of Florence, University of Siena, Ospedale Santa Maria alle Scotte, Istituti Ospitalieri di Cremona, Azienda Socio Sanitaria Territoriale di Cremona
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,910
OpenAlex ID: W7161979367
FWCI:
Cites:
Cited by:
Related to: 10